Payment overview · 2025
General Payments
$153.41
8 reported records · 6 companies
Healthcare provider profile · identity verified
Kenneth Williams, MD
Allopathic & Osteopathic Physicians|Internal Medicine · HOLLY SPRINGS, MS · NPI 1851480974
Verified facts
What the public records show
CMS Open Payments records show Kenneth Williams, MD received $153.41 in general payments during 2025 across 8 reported records.
Abbott Laboratories accounted for 34.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Lumigan by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $53.40 | 34.8% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $26.33 | 17.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $20.26 | 13.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.18 | 13.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $19.57 | 12.8% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $13.67 | 8.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $153.41 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $39.00 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $26.33 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $20.26 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $20.18 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $19.57 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $14.40 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $13.67 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LINZESS linzess |
2025 | Linzess | 2024 | 81 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 65 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
81 | 20 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
65 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 298 | 60 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 295 | 41 |
| Omeprazole | Omeprazole | 291 | 53 |
| Atorvastatin Calcium | Atorvastatin Calcium | 232 | 41 |
| Losartan Potassium | Losartan Potassium | 215 | 41 |
| Tramadol Hcl | Tramadol Hcl | 188 | 60 |
| Furosemide | Furosemide | 169 | 43 |
| Metformin Hcl | Metformin Hcl | 168 | 31 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 168 | 36 |
| Diclofenac Sodium | Diclofenac Sodium | 167 | 42 |
| Pantoprazole Sodium | Pantoprazole Sodium | 159 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 145 | 26 |
| Meloxicam | Meloxicam | 145 | 47 |
| Simvastatin | Simvastatin | 127 | 28 |
| Gabapentin | Gabapentin | 121 | 32 |
| Glimepiride | Glimepiride | 118 | 22 |
| Alprazolam | Alprazolam | 116 | 21 |
| Potassium Chloride | Potassium Chloride | 116 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 115 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 112 | 39 |
| Lisinopril | Lisinopril | 112 | 26 |
| Carvedilol | Carvedilol | 106 | 19 |
| Allopurinol | Allopurinol | 105 | 24 |
| Oxycodone Hcl | Oxycodone Hcl | 103 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 100 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 93 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 90 | 24 |
| Methylprednisolone | Methylprednisolone | 89 | 70 |
| Farxiga | Dapagliflozin Propanediol | 87 | 13 |
| Tamsulosin Hcl | Tamsulosin Hcl | 87 | 18 |
| Linzess | Linaclotide | 81 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 80 | 21 |
| Lovastatin | Lovastatin | 78 | 19 |
| Montelukast Sodium | Montelukast Sodium | 76 | 12 |
| Fluconazole | Fluconazole | 75 | 24 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 73 | 11 |
| Eliquis | Apixaban | 66 | 13 |
| Metoprolol Succinate | Metoprolol Succinate | 66 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 65 | 16 |
| Januvia | Sitagliptin Phosphate | 65 | suppressed |
| Levetiracetam | Levetiracetam | 65 | suppressed |
| Ozempic | Semaglutide | 65 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 63 | 16 |
| Prednisone | Prednisone | 63 | 18 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 61 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 56 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 56 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 55 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 54 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 54 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 53 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 53 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 52 | 16 |
| Cefdinir | Cefdinir | 52 | 45 |
| Doxazosin Mesylate | Doxazosin Mesylate | 52 | suppressed |
| Jardiance | Empagliflozin | 52 | 14 |
| Clonazepam | Clonazepam | 51 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 51 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 51 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 50 | 13 |
| Levothyroxine Sodium | Levothyroxine Sodium | 48 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 48 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 47 | 13 |
| Azithromycin | Azithromycin | 44 | 40 |
| Celecoxib | Celecoxib | 43 | suppressed |
| Pregabalin | Pregabalin | 43 | 14 |
| Tradjenta | Linagliptin | 43 | suppressed |
| Glipizide | Glipizide | 42 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 42 | suppressed |
| Famotidine | Famotidine | 41 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 40 | suppressed |
| Xarelto | Rivaroxaban | 40 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 39 | suppressed |
| Entresto | Sacubitril/Valsartan | 39 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 39 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 38 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 37 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 36 | 19 |
| Clonidine Hcl | Clonidine Hcl | 36 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 35 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 34 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 32 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 32 | suppressed |
| Bumetanide | Bumetanide | 31 | suppressed |
| Ezetimibe | Ezetimibe | 30 | suppressed |
| Atenolol | Atenolol | 29 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 28 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 28 | suppressed |
| Metolazone | Metolazone | 28 | suppressed |
| Olanzapine | Olanzapine | 28 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Mounjaro | Tirzepatide | 27 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 26 | 21 |
| Cefuroxime | Cefuroxime Axetil | 25 | 21 |
| Etodolac | Etodolac | 25 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 25 | suppressed |
| Niacin Er | Niacin | 25 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | 16 |
| Ibuprofen | Ibuprofen | 24 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Mirtazapine | Mirtazapine | 23 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 22 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 22 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | suppressed |
| Buprenorphine | Buprenorphine | 20 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 20 | suppressed |
| Trulicity | Dulaglutide | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | suppressed |
| Metronidazole | Metronidazole | 18 | 14 |
| Trazodone Hcl | Trazodone Hcl | 18 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Brilinta | Ticagrelor | 16 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 16 | suppressed |
| Famciclovir | Famciclovir | 15 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 15 | suppressed |
| Movantik | Naloxegol Oxalate | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Lorazepam | Lorazepam | 14 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 14 | suppressed |
| Spironolactone | Spironolactone | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Efavirenz-Emtric-Tenofov Disop | Efavirenz/Emtricit/Tenofovr Df | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 13 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 13 | suppressed |
| Trimethoprim | Trimethoprim | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Lumigan | Bimatoprost | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Carbamazepine Er | Carbamazepine | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 11 | suppressed |
| Xifaxan | Rifaximin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $153.41 · 8 records | Abbott Laboratories | Dexcom G6 Transmitter, FREESTYLE LIBRE, FREESTYLE LIBRE 3, Kerendia, LINZESS, Ozempic, REXULTI | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Linzess play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error